Tarsus Pharmaceuticals Inc

NASDAQ:TARS 4:00:00 PM EDT

33.89

+1.62 (+5.02%)

4:02:02 PM EDT: $33.89 0.00 (0.00%)

Market Cap (Intraday)	1.35B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$43.61 Million
Adjusted EPS	-$0.94

See more estimates

10-Day MA	$32.99
50-Day MA	$28.65
200-Day MA	$30.09

See more pivots

Tarsus Pharmaceuticals Inc Stock, NASDAQ:TARS

15440 Laguna Canyon Road, Suite 160, Irvine, California 92618

United States of America

Phone: +1.949.409.9820

Number of Employees: 244

http://tarsusrx.com

Description

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.